+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial



Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial



Journal of the American Academy of Child and Adolescent Psychiatry 42(1): 22-29



To date, two randomized, double-blind trials of serotonin reuptake inhibitors (SRIs) have shown that antidepressant drugs are effective in treating adolescent depression. In contrast, tricyclic antidepressants (TCAs) are not superior to placebo. This has led to a serotonin hypothesis in this age group. This study explores this hypothesis and compares paroxetine, a specific SRI, with clomipramine, a TCA with SRI activity. One hundred twenty-one adolescents (aged 12-20 years) with major depression were enrolled and randomized (stratified for age) to 20 or 40 mg of paroxetine or 75 mg or 150 mg of clomipramine for 8 weeks. Primary outcome measurements were the Clinical Global Impression (CGI) scale and the Montgomery and Asberg Depression Rating Scale (MADRS). Of the 121 patients, 58 received clomipramine and 63 paroxetine. Based on intent-to-treat analysis, both agents had similar efficacy, with no effect of age; 48.3% and 58.2% of the subjects receiving clomipramine and 65.1% and 59.3% of those receiving paroxetine were rated responders on the MADRS and CGI scales, respectively. Study withdrawals were frequent in both groups (41% and 31%, respectively), but side effects were significantly more frequent with clomipramine (69% versus 49.2%, respectively; p = .027). Paroxetine and clomipramine exhibit similar efficacy in adolescent depression. These data support the serotonin hypothesis but do not confirm it in the absence of a placebo arm. Given the adverse event profile of clomipramine, specific SRIs should be preferred. However, more placebo-controlled studies are needed to establish definitively the efficacy of SRIs in this age group.

(PDF emailed within 1 workday: $29.90)

Accession: 046920213

Download citation: RISBibTeXText

PMID: 12500073


Related references

Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. Journal of the American Academy of Child & Adolescent Psychiatry 42(1): 22-29, 2003

Multicenter double-blind randomized parallel-group clinical trial of effectiveness of the combination clomipramine plus lithium carbonate versus clomipramine plus placebo in the treatment of unipolar major depression. European Neuropsychopharmacology 10(Suppl. 3): S249, 2000

Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. Journal of Affective Disorders 76(1-3): 191-200, 2003

Multicenter Double-Blind Study of the Efficacy of Paroxetine versus Clomipramine in Elderly Patients with Major Depression. Journal of Aging & PharmacoTherapy 13(2): 7-19, 2007

Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 45(6): 709-719, 2006

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Archives of General Psychiatry 61(11): 1153-1162, 2004

Paroxetine versus amitriptyline in patients with recurrent major depression: A double-blind trial. International Journal of Psychiatry in Clinical Practice 6(1): 23-29, 2002

A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Journal of Clinical Psychiatry 58(3): 112-118, 1997

Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 43(11): 1387-1396, 2004

Multicenter double-blind study comparing the efficacy and tolerance of paroxetine and clomipramine in reactive depression in the elderly patient. L'Encephale 19(3): 257-261, 1993

Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. International Clinical Psychopharmacology 17(1): 27-32, 2002

Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 18(6): 470-477, 1995

Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry and Clinical Neurosciences 61(3): 295-307, 2007

Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 330(7490): 503, 2005

Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin. Acta Psychiatrica Scandinavica 77(6): 683-688, 1988